English, Article edition: Applying Epidemiology-Based Outcomes Research to Clinical Decision-Making: A Hypothetical Model of Biotechnology Therapy in Gram-Negative Sepsis Edward C.Y. Wang; Thaddeus H. Grasela; Cynthia A. Walawander

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118948
Physical Description
  • article
Language
  • English

Edition details

Title
  • Applying Epidemiology-Based Outcomes Research to Clinical Decision-Making: A Hypothetical Model of Biotechnology Therapy in Gram-Negative Sepsis
Author
  • Edward C.Y. Wang
  • Thaddeus H. Grasela
  • Cynthia A. Walawander
Physical Description
  • article
Notes
  • Objective: Sepsis occurs in a heterogeneous population. A prospective nationwide surveillance study found that populations stratified by infection type had significant differences in the incidence of sepsis syndrome, rate of complications and mortality. The objective of this study was to explore whether successful identification of population-specific risk factors for disease-associated morbidity and mortality may allow for more accurate assessment of the cost effectiveness of treatment strategies. Design: A decision analytic model was developed using outcomes data on incidence and resolution of major complications in sepsis syndrome. Healthcare resource utilisation data were based on length of hospital stay, intensive care unit stay versus hospital ward stay, and cost of treating sepsis-related complications. Setting: This modelling study, conducted from the perspective of the healthcare institution, used actual outcomes data on 2 infection-specific patient populations. Patients and participants: The 2 populations studied were patients with nosocomial respiratory tract infection or community-acquired urinary tract infection who subsequently developed sepsis syndrome. Interventions: Treatment options modelled were standard therapy plus biotechnology therapy versus standard therapy alone in the treatment of gram-negative sepsis complications. Main outcome measures and results: The incremental cost-effectiveness ratios differed between the 2 study populations, due to differences in the incidence and rate of resolution of major sepsis-associated complications. The use of biotechnology therapy is always more cost effective in the respiratory tract infection population. Conclusions: Cost-effectiveness results for a therapy may change when the epidemiology of the disease state is known and incorporated into the decision analytic model. An infection-specific approach is important in the treatment of sepsis.
  • Pharmacoeconomics, Sepsis, Cost-analysis, Respiratory-tract-infections, Urinary-tract-infections, Antibacterials, Nebacumab, Edobacomab, Research-and-development, Gram-negative-infections, Mortality, Biotechnology, Monoclonal-antibodies
  • RePEc:wkh:phecon:v:15:y:1999:i:4:p:385-393
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment